Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Department of Trauma and Orthopaedic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
J Bone Miner Res. 2022 Aug;37(8):1580-1591. doi: 10.1002/jbmr.4630. Epub 2022 Jul 8.
Hereditary hypophosphatemic rickets with hypercalciuria (HHRH) represents an FGF23-independent disease caused by biallelic variants in the solute carrier family 34-member 3 (SLC34A3) gene. HHRH is characterized by chronic hypophosphatemia and an increased risk for nephrocalcinosis and rickets/osteomalacia, muscular weakness, and secondary limb deformity. Biochemical changes, but no relevant skeletal changes, have been reported for heterozygous SLC34A3 carriers. Therefore, we assessed the characteristics of individuals with biallelic and monoallelic SLC34A3 variants. In 8 index patients and 5 family members, genetic analysis was performed using a custom gene panel. The skeletal assessment comprised biochemical parameters, areal bone mineral density (aBMD), and bone microarchitecture. Pathogenic SLC34A3 variants were revealed in 7 of 13 individuals (2 homozygous, 5 heterozygous), whereas 3 of 13 carried monoallelic variants of unknown significance. Whereas both homozygous individuals had nephrocalcinosis, only one displayed a skeletal phenotype consistent with HHRH. Reduced to low-normal phosphate levels, decreased tubular reabsorption of phosphate (TRP), and high-normal to elevated values of 1,25-OH -D accompanied by normal cFGF23 levels were revealed independently of mutational status. Interestingly, individuals with nephrocalcinosis showed significantly increased calcium excretion and 1,25-OH -D levels but normal phosphate reabsorption. Furthermore, aBMD Z-score <-2.0 was revealed in 4 of 8 heterozygous carriers, and HR-pQCT analysis showed a moderate decrease in structural parameters. Our findings highlight the clinical relevance also of monoallelic SLC34A3 variants, including their potential skeletal impairment. Calcium excretion and 1,25-OH -D levels, but not TRP, were associated with nephrocalcinosis. Future studies should investigate the effects of distinct SLC34A3 variants and optimize treatment and monitoring regimens to prevent nephrocalcinosis and skeletal deterioration. © 2022 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
遗传性低血磷性佝偻病伴高钙尿症(HHRH)是一种由溶质载体家族 34 成员 3(SLC34A3)基因的双等位基因突变引起的 FGF23 非依赖性疾病。HHRH 的特征是慢性低磷血症以及肾钙质沉着症和佝偻病/骨软化症、肌肉无力和继发性肢体畸形的风险增加。已有报道称杂合子 SLC34A3 携带者存在生化变化,但无相关骨骼变化。因此,我们评估了双等位基因和单等位基因 SLC34A3 变异携带者的特征。在 8 名索引患者和 5 名家庭成员中,使用定制基因面板进行了基因分析。骨骼评估包括生化参数、面积骨密度(aBMD)和骨微观结构。在 13 个人中的 7 个人中发现了致病性 SLC34A3 变异,而 13 个人中的 3 个人携带意义不明的单等位基因变异。虽然两个纯合子个体都有肾钙质沉着症,但只有一个个体表现出与 HHRH 一致的骨骼表型。无论突变状态如何,均发现磷酸盐水平降至低正常水平、磷酸盐肾小管重吸收(TRP)降低、1,25-OH-D 高正常至升高,同时 cFGF23 水平正常。有趣的是,有肾钙质沉着症的个体钙排泄和 1,25-OH-D 水平显著增加,但磷酸盐重吸收正常。此外,在 8 名杂合子携带者中的 4 名中发现 aBMD Z 评分<-2.0,HR-pQCT 分析显示结构参数中度降低。我们的研究结果强调了单等位基因 SLC34A3 变异的临床相关性,包括其潜在的骨骼损伤。钙排泄和 1,25-OH-D 水平,但不是 TRP,与肾钙质沉着症有关。未来的研究应探讨不同 SLC34A3 变异的影响,并优化治疗和监测方案,以预防肾钙质沉着症和骨骼恶化。